Skip to main content

Contribución de la aloreactividad y autoreactividad en el microambiente inflamatorio local en el rechazo mediado por anticuerpos en trasplante renal

PI23/01909

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i en Salud
Call year 2023
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Execution centre INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON (VHIR)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Benefits of Living Over Deceased Donor Kidney Transplantation in Elderly Recipients. A Propensity Score Matched Analysis of a Large European Registry Cohort

  • Toapanta, Néstor|||0000-0001-5983-6863
  • Comas, Jordi|||0000-0001-5257-7029
  • Revuelta, Ignacio|||0000-0002-3584-4516
  • Manonelles, Anna|||0000-0003-2456-388X
  • Facundo, Carme|||0000-0003-1254-5553
  • Pérez-Sáez, María José|||0000-0002-8601-2699
  • Vila, Anna
  • Arcos, Emma
  • Tort, Jaume
  • Giral, Magali|||0000-0001-7641-1592
  • Naesens, Maarten|||0000-0002-5625-0792
  • Kuypers, Dirk RJ.|||0000-0001-5546-9680
  • Åsberg, Anders|||0000-0002-0628-1769
  • Moreso, Francesc|||0000-0002-7267-3963
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
Although kidney transplantation from living donors (LD) offers better long-term results than from deceased donors (DD), elderly recipients are less likely to receive LD transplants than younger ones. We analyzed renal transplant outcomes from LD versus DD in elderly recipients with a propensity-matched score. This retrospective, observational study included the first single kidney transplants in recipients aged ≥65 years from two European registry cohorts (2013-2020, n = 4,257). Recipients of LD (n = 408), brain death donors (BDD, n = 3,072), and controlled cardiocirculatory death donors (cDCD, n = 777) were matched for donor and recipient age, sex, dialysis time and recipient diabetes. Major graft and patient outcomes were investigated. Unmatched analyses showed that LD recipients were more likely to be transplanted preemptively and had shorter dialysis times than any DD type. The propensity score matched Cox's regression analysis between LD and BDD (387-pairs) and LD and cDCD (259-pairs) revealing a higher hazard ratio for graft failure with BDD (2.19 [95% CI: 1.16-4.15], p = 0.016) and cDCD (3.38 [95% CI: 1.79-6.39], p < 0.001). One-year eGFR was higher in LD transplants than in BDD and cDCD recipients. In elderly recipients, LD transplantation offers superior graft survival and renal function compared to BDD or cDCD. This strategy should be further promoted to improve transplant outcomes.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

On the relative relevance of donor-derived cell-free DNA and urinary chemokines as noninvasive biomarkers for the diagnosis of kidney allograft rejection

  • Carrera Muñoz, Claudia
  • Font Miñarro, Cristina
  • Juvé Torres, Mariona
  • Castañeda Amado, Zaira Ivette
  • Torres, Irina B.
  • Casanova, Franc
  • Gabaldon, Maria Alejandra
  • Alvarez, Tiffany
  • Cantenys, Sergi
  • KERVELLA, Delphine
  • Meneghini, Maria
  • Crespo, Elena
  • Zamora Carrillo, Jorge Ivan
  • Patricio-Liébana, Marc
  • Sellarès , Joana
  • Perelló, Manel
  • Martínez Gallo, Mónica
  • Moreso, Francesc
  • Bestard, Oriol
Biomarkers; Donor-derived cell-free DNA; Rejection, Biomarcadores; ADN libre de células derivado de donantes; Rechazo, Biomarcadors; ADN lliure de cèl·lules derivat de donants; Rebuig, Donor-derived cell-free deoxyribonucleic acid (DNA) (dd-cfDNA) and urinary chemokines are promising noninvasive biomarkers for kidney allograft rejection, but direct comparative data are lacking. In this prospective pilot study, we analyzed 194 biopsies (101 for-cause, 93 surveillance) paired with dd-cfDNA and urinary chemokine (CXCL9, CXCL10, CCL2, VEGF-A) concentrations in kidney transplant recipients. We evaluated their correlation, diagnostic accuracy for rejection phenotypes, and integration into diagnostic models with clinical and immunologic variables. Rejection was diagnosed in 32.5% of biopsies, predominantly antibody-mediated. dd-cfDNA showed strong diagnostic performance in both for-cause (area under the receiver operating characteristic curve [AUC] 0.85) and surveillance (AUC 0.91) biopsies. Conversely, urinary chemokines, particularly the composite Score4, showed accuracy mainly in for-cause biopsies (AUC 0.76). Remarkably, Score4 combined with donor-specific antibodies showed similar performance as dd-cfDNA + donor-specific antibodies (AUC 0.90) in for-cause biopsies. Internal bootstrap validation, including calibration metrics, confirmed the consistency of the models. dd-cfDNA provides robust diagnostic accuracy for kidney allograft rejection across distinct clinical settings. Urinary chemokine measures, especially Score4, may offer valuable diagnostic utility in for-cause biopsies. These findings support context-specific integration of noninvasive biomarkers and represent the first direct comparison of dd-cfDNA and urinary chemokines, informing personalized approaches to rejection monitoring., The results reported in this manuscript were supported by competitive research grants from the Instituto de Salud Carlos III (isciii) PI18/01832, PI23/01909, PI22/00749, PI22/01019, RICORS2040-Renal (Redes de Investigación Cooperativa Orientadas a Resultados en Salud financed by Instituto Salud Carlos III and cofinanced by the European Union (O.B.), RD21/0005/0016) and European Union (ERDF/ESF)-A way to build Europe (O.B.).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

On the relative relevance of donor-derived cell-free DNA and urinary chemokines as noninvasive biomarkers for the diagnosis of kidney allograft rejection

  • Carrera Muñoz, Claudia
  • Font Miñarro, Cristina
  • Juvé Torres, Mariona
  • Castañeda Amado, Zaira Ivette
  • Torres, Irina B.
  • Casanova, Franc
  • Gabaldon, Maria Alejandra
  • Alvarez, Tiffany
  • Cantenys, Sergi
  • KERVELLA, Delphine
  • Meneghini, Maria
  • Crespo, Elena
  • Zamora Carrillo, Jorge Ivan
  • Patricio-Liébana, Marc
  • Sellarès , Joana
  • Perelló, Manel
  • Martínez Gallo, Mónica
  • Moreso, Francesc
  • Bestard, Oriol
Biomarkers; Donor-derived cell-free DNA; Rejection, Biomarcadores; ADN libre de células derivado de donantes; Rechazo, Biomarcadors; ADN lliure de cèl·lules derivat de donants; Rebuig, Donor-derived cell-free deoxyribonucleic acid (DNA) (dd-cfDNA) and urinary chemokines are promising noninvasive biomarkers for kidney allograft rejection, but direct comparative data are lacking. In this prospective pilot study, we analyzed 194 biopsies (101 for-cause, 93 surveillance) paired with dd-cfDNA and urinary chemokine (CXCL9, CXCL10, CCL2, VEGF-A) concentrations in kidney transplant recipients. We evaluated their correlation, diagnostic accuracy for rejection phenotypes, and integration into diagnostic models with clinical and immunologic variables. Rejection was diagnosed in 32.5% of biopsies, predominantly antibody-mediated. dd-cfDNA showed strong diagnostic performance in both for-cause (area under the receiver operating characteristic curve [AUC] 0.85) and surveillance (AUC 0.91) biopsies. Conversely, urinary chemokines, particularly the composite Score4, showed accuracy mainly in for-cause biopsies (AUC 0.76). Remarkably, Score4 combined with donor-specific antibodies showed similar performance as dd-cfDNA + donor-specific antibodies (AUC 0.90) in for-cause biopsies. Internal bootstrap validation, including calibration metrics, confirmed the consistency of the models. dd-cfDNA provides robust diagnostic accuracy for kidney allograft rejection across distinct clinical settings. Urinary chemokine measures, especially Score4, may offer valuable diagnostic utility in for-cause biopsies. These findings support context-specific integration of noninvasive biomarkers and represent the first direct comparison of dd-cfDNA and urinary chemokines, informing personalized approaches to rejection monitoring., The results reported in this manuscript were supported by competitive research grants from the Instituto de Salud Carlos III (isciii) PI18/01832, PI23/01909, PI22/00749, PI22/01019, RICORS2040-Renal (Redes de Investigación Cooperativa Orientadas a Resultados en Salud financed by Instituto Salud Carlos III and cofinanced by the European Union (O.B.), RD21/0005/0016) and European Union (ERDF/ESF)-A way to build Europe (O.B.).